Loading
Argenica Therapeutics Limited Stock: price and insider trades · Australia
1 insider bought €12k of shares over the last 90 days, the latest filed 29 Sept 2026.
Argenica Therapeutics Limited: what insiders have been doing
Argenica Therapeutics Limited has a thin disclosure history in our data (latest filing: 29 September 2026). New filings will appear here as soon as they are published. This summary is built from ASX disclosures alone and does not predict where the share price will go.
Insider Decl.
1
Thresholds
n/a
Buy Volume
€12,316
1 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleJeannette Joughin1 buy
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended June 2025 · cache
A$0.15
Analyst consensus
Income statement
EBITDA-A$7.2M
Net income-A$7.2M-24.9% margin
Valuation
P/Book3.3x
Beta1.08
Balance sheet & cash
Market capA$19.3M
Free Cash Flow-A$5.7M
Profitability & ownership
ROE-20.8%
ROA-11.2%
% insiders32.3%
% institutions0.7%
Last declaration on 29 September 2026
Declarations1 total
142,643 shares@ A$0.14100.0% of flowShareASXISIN AU0000150328ASX:2924-03141212-6A1346221
Canonical exit: 28 Dec 2026 (T+90)
1 of 1 declaration
About Argenica Therapeutics Limited
Argenica Therapeutics Limited is an Australian biopharmaceutical company focused on developing treatments for neurodegenerative diseases. It is listed on the XASX market.
